With the recent approval of the first two interchangeable biosimilars to Amgen’s PROLIA® and XGEVA® by the US FDA in March 2024, the overall count
The final versions of the updated Guidelines for Patent Examination and the Implementing Rules for the Patent Law were released by the China National Intellectual
Pembrolizumab, a monoclonal antibody marketed under the brand name Keytruda®, was Merck & Co’s highest-grossing product in FY 2023 with sales of about 25 billion
Following up on our previous post on looming biosimilar approvals over Eylea®(Aflibercept), on March 4, Biocon Biologics Limited (BBL), a subsidiary of Biocon Limited, announced
For many years, conventional medical approaches involving medication and surgery have significantly enhanced individuals’ well-being. However, certain diseases persist without a definitive cure, and these
Chimeric Antigen Receptor (CAR)-T cell therapy, a groundbreaking form of immunotherapy harnessing a patient’s own T cells to combat cancer, has undergone remarkable advancements over
